T1	PROC 46 76	Estudio con asignacion al azar
T2	CHEM 116 127	gabapentina
#1	AnnotatorNotes T2	C0060926; gabapentin; Organic Chemical · Pharmacologic Substance
T3	DISO 190 203	Herpes Zoster
#2	AnnotatorNotes T3	C0019360; Herpes zoster disease; Disease or Syndrome
T4	PROC 204 212	previene
#3	AnnotatorNotes T4	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T5	DISO 232 255	neuralgia postherpética
#4	AnnotatorNotes T5	C0032768; Postherpetic neuralgia; Disease or Syndrome
T6	PROC 279 320	Ensayo clínico, aleatorizado, doble-ciego
T7	PROC 809 823	diagnósticados
T8	PROC 326 357	evaluar la eficacia y seguridad
#5	AnnotatorNotes T8	C0511730; Identify product efficacy and safety issues; Health Care Activity
T9	CHEM 364 375	gabapentina
#6	AnnotatorNotes T9	C0060926; gabapentin; Organic Chemical · Pharmacologic Substance
T10	PROC 385 392	placebo
#7	AnnotatorNotes T10	C0032042; Placebos; Therapeutic or Preventive Procedure
T11	PROC 399 409	prevención
#8	AnnotatorNotes T11	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T12	DISO 416 439	neuralgia postherpética
#9	AnnotatorNotes T12	C0032768; Postherpetic neuralgia; Disease or Syndrome
T13	DISO 463 486	Neuralgia Postherpética
#10	AnnotatorNotes T13	C0032768; Postherpetic neuralgia; Disease or Syndrome
T14	PROC 539 550	diagnóstico
#11	AnnotatorNotes T14	C0011900; Diagnosis; Diagnostic Procedure
T15	DISO 554 581	herpes zoster no complicado
#12	AnnotatorNotes T15	C0348190; Zoster without complication; Disease or Syndrome
T16	PROC 683 686	EVA
#13	AnnotatorNotes T16	C0042815; Visual Analog Pain Scale; Diagnostic Procedure | C2960689; Assessment using visual analog pain scale; Health Care Activity
T17	PROC 731 742	tratamiento
#14	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	CHEM 756 767	gabapentina
#15	AnnotatorNotes T18	C0060926; gabapentin; Organic Chemical · Pharmacologic Substance
T19	CHEM 770 796	antidepresivos tricíclicos
#16	AnnotatorNotes T19	C0003290; Tricyclic Antidepressive Agents; Pharmacologic Substance
T20	DISO 827 849	insuficiencia hepática
#17	AnnotatorNotes T20	C0085605; Liver Failure; Disease or Syndrome | C1306571; Hepatic Insufficiency; Pathologic Function
T21	DISO 882 899	hipersensibilidad
#18	AnnotatorNotes T21	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T22	CHEM 940 951	excipientes
#19	AnnotatorNotes T22	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T23	DISO 968 996	insuficiencia renal alterada
#20	AnnotatorNotes T23	C0341677; Impaired renal function disorder; Disease or Syndrome
T24	PROC 998 1002	Clcr
#21	AnnotatorNotes T24	C0373595; Creatinine clearance measurement; Laboratory Procedure
T25	ANAT 1056 1063	cutánea
#22	AnnotatorNotes T25	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T26	ANAT 1066 1074	visceral
#23	AnnotatorNotes T26	C0042779; Viscera; Body Part, Organ, or Organ Component
T27	DISO 1079 1081	HZ
#24	AnnotatorNotes T27	C0019360; Herpes zoster disease; Disease or Syndrome
T28	DISO 1093 1101	lesiones
#25	AnnotatorNotes T28	C0221198; Lesion; Finding
T29	ANAT 1112 1121	dermatoma
#26	AnnotatorNotes T29	C0392338; Cutaneous Receptive Fields; Body Location or Region
T30	DISO 1135 1155	afectación oftálmica
T31	PROC 1171 1197	tratamiento inmunosupresor
#27	AnnotatorNotes T31	C0021079; Therapeutic immunosuppression; Therapeutic or Preventive Procedure
T32	PROC 1222 1233	diagnóstico
#28	AnnotatorNotes T32	C0011900; Diagnosis; Diagnostic Procedure
T33	DISO 1237 1254	inmunodeficiencia
#29	AnnotatorNotes T33	C0021051; Immunologic Deficiency Syndromes; Disease or Syndrome
T34	PROC 1274 1301	tratamiento inmunomodulador
T35	CHEM 1303 1313	interferon
#30	AnnotatorNotes T35	C0021747; Interferons; Amino Acid, Peptide, or Protein · Immunologic Factor
T36	CHEM 1286 1301	inmunomodulador
#31	AnnotatorNotes T36	C1527392; Immunomodulators; Immunologic Factor · Pharmacologic Substance
T37	DISO 623 628	dolor
#32	AnnotatorNotes T37	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T38	DISO 664 669	dolor
#33	AnnotatorNotes T38	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T39	ANAT 841 849	hepática
#34	AnnotatorNotes T39	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T40	CHEM 905 921	sustancia activa
T41	ANAT 982 987	renal
#35	AnnotatorNotes T41	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T42	ANAT 1146 1155	oftálmica
#36	AnnotatorNotes T42	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T43	CHEM 1183 1197	inmunosupresor
#37	AnnotatorNotes T43	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T44	DISO 177 185	sintomas
#38	AnnotatorNotes T44	C1457887; Symptoms; Sign or Symptom
T45	Date 13 17	2013
T46	LIVB 84 93	pacientes
#39	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T47	Spec_cue 110 112	si
T48	Duration 144 160	las primeras 72h
T49	LIVB 513 522	Pacientes
#40	AnnotatorNotes T49	C0030705; Patients; Patient or Disabled Group
T50	Age 523 533	>= 50 años
T52	Duration 585 593	< de 72h
T53	LIVB 609 618	Pacientes
#41	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T56	LIVB 718 727	Pacientes
#42	AnnotatorNotes T56	C0030705; Patients; Patient or Disabled Group
T57	LIVB 799 808	Pacientes
#43	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	LIVB 858 867	Pacientes
#44	AnnotatorNotes T58	C0030705; Patients; Patient or Disabled Group
T59	LIVB 954 963	Pacientes
#45	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T61	LIVB 1016 1025	Pacientes
#46	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T62	LIVB 1158 1167	Pacientes
#47	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T63	Duration 1201 1220	los últimos 3 meses
T64	Duration 1318 1339	las últimas 4 semanas
A1	Assertion T4 Speculated
A2	Status T21 History_of
A3	Status T36 History_of
A4	Status T34 History_of
A5	Status T35 History_of
#48	AnnotatorNotes T1	C0034656; Randomization; Research Activity
#49	AnnotatorNotes T6	C0013072; Double-Blind Method; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity
#50	AnnotatorNotes T7	C0011900; Diagnosis; Diagnostic Procedure
#51	AnnotatorNotes T40	C0574031; Biologically Active Substance; Biologically Active Substance 
#52	AnnotatorNotes T34	C1963758; Immunomodulation; Therapeutic or Preventive Procedure
T51	Neg_cue 568 570	no
T54	Quantifier_or_Qualifier 571 581	complicado
A6	Assertion T54 Negated
#53	AnnotatorNotes T54	C0231242; Complicated; Functional Concept
R1	Experiences Arg1:T46 Arg2:T2	
R2	Speculation Arg1:T47 Arg2:T4	
R3	Used_for Arg1:T2 Arg2:T4	
R4	Has_Duration_or_Interval Arg1:T2 Arg2:T48	
R5	Has_Duration_or_Interval Arg1:T44 Arg2:T48	
R6	Overlap Arg1:T2 Arg2:T44	
R7	Causes Arg1:T3 Arg2:T44	
R8	Experiences Arg1:T46 Arg2:T44	
R9	Experiences Arg1:T46 Arg2:T3	
R10	Experiences Arg1:T46 Arg2:T4	
R11	Experiences Arg1:T46 Arg2:T5	
R12	Before Arg1:T3 Arg2:T5	
R13	Before Arg1:T4 Arg2:T5	
R14	Used_for Arg1:T9 Arg2:T11	
R15	Used_for Arg1:T10 Arg2:T11	
R16	Before Arg1:T11 Arg2:T12	
R17	Has_Age Arg1:T49 Arg2:T50	
R18	Negation Arg1:T51 Arg2:T54	
R19	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T54	
R20	Has_Duration_or_Interval Arg1:T15 Arg2:T52	
R21	Experiences Arg1:T49 Arg2:T15	
T55	Quantifier_or_Qualifier 629 647	moderado a intenso
#54	AnnotatorNotes T55	C1299393; Moderate to severe; Qualitative Concept
R22	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T55	
T60	Result_or_Value 687 690	>=4
R23	Has_Result_or_Value Arg1:T16 Arg2:T60	
R25	Experiences Arg1:T53 Arg2:T37	
R27	Experiences Arg1:T53 Arg2:T38	
R28	Experiences Arg1:T53 Arg2:T16	
R29	Experiences Arg1:T56 Arg2:T17	
R30	Used_for Arg1:T18 Arg2:T17	
R31	Used_for Arg1:T19 Arg2:T17	
R32	Location_of Arg1:T39 Arg2:T20	
R33	Experiences Arg1:T57 Arg2:T20	
T65	Quantifier_or_Qualifier 850 855	grave
#55	AnnotatorNotes T65	C1547227; Severe -Severity of Illness Code; Intellectual Product
R34	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T65	
R35	Experiences Arg1:T58 Arg2:T21	
R36	Causes Arg1:T40 Arg2:T21	
R37	Causes Arg1:T22 Arg2:T21	
R38	Location_of Arg1:T41 Arg2:T23	
R39	Experiences Arg1:T59 Arg2:T23	
R40	Experiences Arg1:T59 Arg2:T24	
T66	Result_or_Value 1003 1012	<79ml/min
R41	Has_Result_or_Value Arg1:T24 Arg2:T66	
R42	Experiences Arg1:T61 Arg2:T27	
R43	Experiences Arg1:T61 Arg2:T28	
T67	Quantifier_or_Qualifier 1083 1092	más de 20
R44	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T67	
T68	CONC 1102 1131	fuera del dermatoma adyacente
R45	Location_of Arg1:T68 Arg2:T28	
R46	Experiences Arg1:T61 Arg2:T30	
R47	Location_of Arg1:T42 Arg2:T30	
T69	Observation 1043 1074	diseminación cutánea o visceral
R48	Experiences Arg1:T61 Arg2:T69	
R49	Location_of Arg1:T25 Arg2:T27	
R50	Location_of Arg1:T26 Arg2:T27	
#56	AnnotatorNotes T30	C1389627; Eye damage; Injury or Poisoning (?) | C0743711; eye lesion; Disease or Syndrome (?)
R51	Causes Arg1:T27 Arg2:T28	
R52	Causes Arg1:T27 Arg2:T30	
R53	Causes Arg1:T27 Arg2:T69	
R54	Location_of Arg1:T29 Arg2:T27	
R55	Experiences Arg1:T62 Arg2:T31	
R56	Used_for Arg1:T43 Arg2:T31	
R57	Overlap Arg1:T43 Arg2:T63	
R58	Experiences Arg1:T62 Arg2:T33	
R59	Experiences Arg1:T62 Arg2:T34	
R60	Used_for Arg1:T36 Arg2:T34	
R61	Used_for Arg1:T35 Arg2:T34	
R62	Overlap Arg1:T35 Arg2:T64	
R63	Overlap Arg1:T36 Arg2:T64	
R24	Location_of Arg1:T25 Arg2:T69	
R26	Location_of Arg1:T26 Arg2:T69	
A7	Experiencer T46 Patient
A8	Experiencer T49 Patient
A9	Experiencer T53 Patient
A10	Experiencer T56 Patient
A11	Experiencer T57 Patient
A12	Experiencer T58 Patient
A13	Experiencer T59 Patient
A14	Experiencer T61 Patient
A15	Experiencer T62 Patient
